Health care resource utilization following initiation of a triptan: A retrospective claims analysis

Journal of Managed Care Pharmacy

Volumn 20, Issue 4, 2014, Pages 368-375

  Messali, Andrew ^a,b   Owens, Gary ^c   Bloudek, Lisa ^e   Kori, Shashidhar ^d   Cole, Ashley ^b   Chia, Jenny ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

^c Gary Owens Associates   (United States)

^d MAP Pharmaceuticals   (United States)

^e XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; METOPROLOL; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PRESCRIPTION DRUG; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TIMOLOL; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM; VALPROIC ACID; ZOLMITRIPTAN; NARCOTIC ANALGESIC AGENT; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; CHILD; DIAGNOSTIC IMAGING; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; EPISODIC MIGRAINE; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MIDDLE AGED; MIGRAINE; NEWBORN; PHARMACY; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; YOUNG ADULT; FACTUAL DATABASE; HEALTH SERVICE; MEDICATION COMPLIANCE; MIGRAINE DISORDERS; STATISTICS AND NUMERICAL DATA; TIME; UTILIZATION;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MIGRAINE DISORDERS; RETROSPECTIVE STUDIES; TIME FACTORS; TRYPTAMINES; YOUNG ADULT;

EID: 84896912697     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.4.368     Document Type: Article

References (29)

1. Lipton RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache. 2007;(47 Suppl 1):S2-S9.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57.
3. Gobel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia. 1994;14(2):97-106.
4. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R. A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia. 1992;12(4):229-37; discussion 186.
5. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19(3):333-39.
6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813-18.
7. Kleinke JD. The price of progress: prescription drugs in the health care market. Health Aff (Millwood). 2001;20(5):43-60.
8. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-80.
9. Panconesi A, Pavone E, Franchini M, et al. Triptans: low utilization and high turnover in the general population. Cephalalgia. 2010;30(5):576-81.
10. Ifergane G, Wirguin I, Shvartzman P. Triptans-why once? Headache. 2006;46(8):1261-63.
11. Katic BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: what does it mean, why does it matter? Headache. 2010;50(1):117-29.
12. Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137-44. Available at: http://amcp.org/WorkArea/DownloadAsset. aspx?id=7121.
13. Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. Eur J Clin Pharmacol. 2007;63(8):801-07.
14. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Single use of sumatriptan: a patient interview study. Headache. 2003;43(2):109-16.
15. Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol. 1996;50(3):161-65.
16. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-62.
17. Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? Headache. 2010;50(10):1597-611.
18. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179-82.
19. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache. 2012;52(1):18-36.
20. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache. 1996;36(9):538-41.
21. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med. 1999;159(8):857-63.
22. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther. 1999;21(1):190-204.
23. Streator SE. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated health care costs. Am J Manag Care. 1996;2(2):139-43.
24. Wu J, Hughes MD, Hudson MF, Wagner PJ. Antimigraine medication use and associated health care costs in employed patients. J Headache Pain. 2012;13(2):121-27.
25. Coukell AJ, Lamb HM. Sumatriptan. A pharmacoeconomic review of its use in migraine. Pharmacoeconomics. 1997;11(5):473-90.
26. Caro JJ, Getsios D. Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opin Pharmacother. 2002;3(3):237-48.
27. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology. 2004;63(3):427-35.
28. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches)-clinical lessons. Headache. 2006;(46 Suppl 3): S144-46.
29. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Suppl):S3-S7.